American Medical Systems Holdings, Inc. (AMMD) reported strong fiscal third quarter results. For the quarter, earnings per share was 27 cents, beating the Zacks Consensus Estimate of 20 cents and the year-ago earnings of 18 cents. Earnings per share for the reported quarter were also ahead of the company’s previous guidance of 17 to 21 cents.   Sales   Total sales for the quarter increased 4.9% year over year to $123.2 million. Excluding an unfavorable foreign currency translation (FX), net sales increased 6.7% year over year. On a geographic basis, U.S. sales accounted for roughly 75% of total sales and increased 9.2% year over year. International sales declined 6.1% year over year.   In terms of business segments: Men’s health revenues increased 6.6% year over year to $54.7 million. Growth was primarily due to higher sales of the erectile restoration system.   Women’s health revenues increased 4% year over

...

American Medical Systems Holdings, Inc. (AMMD) recently won a new contract to supply three of its female stress urinary incontinence (SUI) treatment devices, Monarc Subfascial Hammock, MiniArc Single-Incision Sling, and SPARC Sling System, in the U.K. The contract was awarded by the public healthcare provider of the U.K. , the National Healthcare Services (NHS), as part of its multiple-awardees contract. Financial details of the contract are yet to be disclosed.  The devices will be available to women treated in any NHS hospital in the region and supported by the Normanton centre, U.K. The Monarc device is one of the leading transobturator slings that bring relief to women suffering from SUI. It has been estimated that more than 600,000 women have been implanted with the Monarc, MiniArc and SPARC systems globally.  We think that the new contract is a shot in the arm for American Medical Systems ...

American Medical Systems Holdings, Inc. (AMMD) amended its offer to exchange up to $250 million and a minimum of $100 million of its outstanding 3.25% Convertible Senior Subordinated Notes due 2036 for newly issued 3.75% Convertible Senior Subordinated Notes due 2041.

The amendment pertains to the coupon rate that was increased 25 basis points to 4.00%. The exchange offer will close on Sep 16, 2009 at midnight. All other terms and conditions for the exchange offer remain unchanged.

The exchange offer calls for exchange of each $1,000 principal amount of its new 3.75%, now 4.00%, Convertible Senior Subordinate Notes due 2041, for each $1,000 principal amount of its 2036 Notes. The 2041 Notes will be converted into cash or shares of the company's common stock at the same conversion rate and price as the 2036 Notes.

The terms and conditions of the exchange offer suggest that holders of 2041 Notes will

...